Market pullbacks and corrections can feel uncomfortable in the moment. But for long-term investors, they are often where the best opportunities are found.
The key is knowing what you want to buy before prices fall.
Here are three ASX 200 shares I would be ready to buy immediately if the market dips again.
Goodman Group (ASX: GMG)
The ASX 200 share I would be watching closely is Goodman Group.
At first glance, Goodman might look like a traditional property company. But its real strength lies in logistics and data infrastructure.
The group develops and manages high-quality industrial properties, many of which are critical to ecommerce supply chains and increasingly, data centre ecosystems.
As demand for digital infrastructure grows, Goodman is positioning itself to benefit from trends like cloud computing and artificial intelligence.
A market pullback could provide a chance to gain exposure to these structural themes through a proven operator.
ResMed Inc (ASX: RMD)
Another ASX 200 share I would target is ResMed.
ResMed sits at the intersection of healthcare and technology, focusing on sleep apnoea devices and connected care solutions. What makes it particularly interesting is how its business model is evolving beyond hardware.
Each device sold opens the door to long-term recurring revenue through masks, software, and patient monitoring platforms.
Concerns around weight loss drugs briefly pressured sentiment, but the reality is that sleep apnoea remains underdiagnosed globally and management sees the drugs as supporting demand rather than limiting it.
If the share price were to dip again, it could be an opportunity to pick up a high-quality global healthcare leader at a more attractive valuation.
Xero Ltd (ASX: XRO)
A third ASX share I would buy on weakness is Xero.
Xero has already built a massive global platform for small business accounting, but the next phase of its growth could be even more interesting.
Rather than just adding new users, the company is focused on deepening its ecosystem. Payments, payroll, lending integrations, and analytics all create additional value for customers and increase revenue per user.
This shift means Xero’s growth is becoming more efficient and potentially more predictable. And while there are concerns that AI will disrupt its business, management doesn’t believe this will be the case. In fact, it expects AI to support the business and has recently announced a deal with AI giant Anthropic.
If volatility returns and the share price pulls back, it could present a compelling entry point into a business with strong long-term potential.
The post 3 ASX 200 shares I would buy immediately if the market dips again appeared first on The Motley Fool Australia.
Should you invest $1,000 in Goodman Group right now?
Before you buy Goodman Group shares, consider this:
Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Goodman Group wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
And right now, Scott thinks there are 5 stocks that may be better buys…
* Returns as of 20 Feb 2026
.custom-cta-button p {
margin-bottom: 0 !important;
}
More reading
- Why these ASX 200 stocks could be perfect for buy and hold investors
- Leading brokers name 3 ASX shares to buy today
- Down 55%, are Xero shares the most overlooked bargain now?
- How to build a winning 10 ASX share portfolio from scratch in 2026
- Brokers name 3 ASX shares to buy right now
Motley Fool contributor James Mickleboro has positions in Goodman Group, ResMed, and Xero. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goodman Group, ResMed, and Xero. The Motley Fool Australia has positions in and has recommended ResMed and Xero. The Motley Fool Australia has recommended Goodman Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.